Late recurrence of stage I malignant melanoma

Mordechai Gutman*, Joseph M. Klausner, Moshe Inbar, Ron R. Rozin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Although the introduction of well‐established risk factors has made the clinical course and prognosis of malignant melanoma disease much more predictable, in a considerable number of patients the disease's course is still not as expected. One group to which this applies are stage I melanoma patients who develop metastatic disease after 10 years or more of a disease‐free interval. In our series of 94 such patients, 6 developed late relapse of their disease. The subsequent survival of these patients did not relate to any of the primary tumors' characteristics, but to the pattern of the late recurrence. Four patients with visceral metastases were dead within 1 to 5 years following relapse, one patient with lymph node involvement is alive with metastases, and another patient with skin metastases has no signs of disease following surgery and immunotherapy. Our conclusion is that malignant melanoma patients should be placed under close follow‐up for the rest of their lives.

Original languageEnglish
Pages (from-to)96-98
Number of pages3
JournalJournal of Surgical Oncology
Issue number2
StatePublished - Oct 1989


  • malignant melanoma
  • prognosis
  • recurrent melanoma


Dive into the research topics of 'Late recurrence of stage I malignant melanoma'. Together they form a unique fingerprint.

Cite this